 Home > Encyclopedia > Disopyramide phosphate

Disopyramide phosphate

Disopyramide phosphate structure

CAS No:
22059-60-5
Formula:
C21H29N3O.H3O4P
Chemical Name:
Disopyramide phosphate
Synonyms:
2-Pyridineacetamide,α-[2-[bis(1-methylethyl)amino]ethyl]-α-phenyl-,phosphate (1:1);2-Pyridineacetamide,α-[2-(diisopropylamino)ethyl]-α-phenyl-,phosphate (1:1);4-Diisopropylamino-2-phenyl-2-(2-pyridyl)butyramide phosphate;Disopyramide phosphate;SC 7031 phosphate;Norpace;Rythmodan;SC 13957;Disopyramide dihydrogen phosphate;Norpace CR;Rythmodul;Diso-Duriles;Dirythmin SA;Rythmodan P;24643-91-2;31758-86-8;79190-73-1
Categories:
Active Pharmaceutical Ingredients > Circulatory System Drugs

Description

Disopyramide phosphate is an organoammonium phosphate. It derives from a disopyramide.|A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.

Disopyramide phosphate Basic Attributes

Molecular Weight：

437.47

Exact Mass：

437.20800

EC Number：

244-756-1

NSC Number：

756744

HScode：

2933399090

Characteristics

PSA：

137

XLogP3：

3.13360

Boiling Point：

505.2ºC at 760 mmHg

Flash Point：

259.4ºC

Water Solubility：

>65.6 [ug/mL]

Vapor Pressure：

2.48E-10mmHg at 25°C

Collision Cross Section：

179.9 Å² [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

Safety Information

Transport codes：

NONH for all modes of transport

wgk germany：

hazard class code：

safety instructions：

RTECS Number：

UR8440000

Marks：

Precautionary statement(s)：

P301 + P312 + P330

Hazard Statements：

H302

GHS Classification：

|Warning|H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]|P264, P270, P301+P312, P330, and P501|Aggregated GHS information provided by 41 companies from 2 notifications to the ECHA C&L Inventory.

Drug Information

MeSH：

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)|A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)

MeSH Entry Terms：

Diisopyramide

Disopyramide phosphate Use and Manufacturing

Uses

Cardiac depressant (anti-arrhythmic).

Use Classification：

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients

Computed Properties

Molecular Weight:437.5
Hydrogen Bond Donor Count:4
Hydrogen Bond Acceptor Count:7
Rotatable Bond Count:8
Exact Mass:437.20795813
Monoisotopic Mass:437.20795813
Topological Polar Surface Area:137
Heavy Atom Count:30
Complexity:459
Undefined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:2
Compound Is Canonicalized:Yes

Drug Function and Efficacy

This product belongs to Class Ia antiarrhythmic drugs. Its electrophysiology and hemodynamics are similar to quinidine. It has the effect of inhibiting the influx of fast sodium ions, prolonging the action potential and effective refractory period, reducing the conduction velocity of the atrium and the accessory bundle, reducing the autonomy of the myocardial conduction fibers, inhibiting the excitability of the atrium and ventricular muscles, and reducing the myocardial contractility. In addition, it has a more obvious anticholinergic effect, so it may accelerate the frequency of the sinus node and the conduction velocity of the atrioventricular junction, but the condition of patients with existing sick sinus syndrome or atrioventricular conduction disorders may still be aggravated. Animal studies have not confirmed teratogenicity.

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Disopyramide phosphate

Disopyramide Phosphate Tablets
Ingredients	The main ingredient of this product is: disopyramide phosphate.
Indication	1 When used in combination with other antiarrhythmic drugs, it can further prolong conduction time and inhibit cardiac function. 2 When used in combination with moderate to large amounts of ethanol, the chances of hypoglycemia and hypotension increase due to synergistic effects. 3 When used in combination with warfarin, the anticoagulant effect can
Specifications	0.1 g

Disopyramide Phosphate Tablets
Ingredients	The main ingredients of this product are: disopyramide phosphate. Molecular formula: C21H29N3OH3PO4 Molecular weight: 437.47
Indication	1 When used in combination with other antiarrhythmic drugs, it can further prolong the conduction time and inhibit cardiac function. 2 When used in combination with moderate to large amounts of ethanol, the chances of hypoglycemia and hypotension increase due to synergistic effects. 3 When used in combination with warfarin, the anticoagulant effect can be more obvious. 4 When used in combination with drug enzyme inducers such as phenobarbital, phenytoin sodium and rifampicin, it can induce the metabolism of this product. In some patients, this product can induce its own metabolism.
Specifications	0.1 g
Manufacturer	Southwest Pharmaceutical Co., Ltd.

Registered Holders

Pcas

United States
Active
SUMITOMO CHEMICAL CO LTD

Belgium
Active
ARCHIMICA S.P.A.

Italy
Active

See More Registered Holders